Compare Bristol-Myers Squibb Co (BMY) vs Rex Fang & Innovation Equity Premium Income ETF (FEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Rex Fang & Innovation Equity Premium Income ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.52 (market cap $116.30B), while Rex Fang & Innovation Equity Premium Income ETF trades at $41.87. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| BMY | FEPI | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $62.37 | $49.54 |
52-Week Low | $42.60 | $38.13 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $41.98, down 1.65% with a bearish technical signal. The ETF employs an aggressive covered call strategy on concentrated AI and mega-cap tech holdings, generating weekly dividends averaging $0.21-0.22 recently. Technical indicators show bearish momentum with resistance at $43 and support at $42, while oscillators remain neutral. The fund's 25% yield attracts retail investors but comes with NAV erosion concerns during market downturns.
FEPI offers high income potential but faces structural limitations from its covered call strategy that caps upside during tech rallies. The concentrated portfolio of high-beta names amplifies downside risk, making it suitable for income-focused investors willing to accept limited capital appreciation. Recent transition to weekly distributions enhances compounding but doesn't address fundamental NAV erosion risks in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →
